Furthermore, activating the JAK2/STAT3 pathway could induce programmed death-ligand 1 (PD-L1) expression, indicating that downregulating STAT3 could activate tumor immunity by inhibiting PD-L1 expression (Wang et al., 2017). The gene discussed is JAK2; the disease is neoplasm.